Immediate Impact
53 standout
Citing Papers
Pancreatic cancer
2025 Standout
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Works of Yi‐Ping Hung being referenced
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
2022
How different is the care of terminal pancreatic cancer patients in inpatient palliative care units and acute hospital wards? A nationwide population-based study
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Yi‐Ping Hung | 327 | 225 | 189 | 44 | 809 | |
| Bassam Estfan | 302 | 194 | 129 | 45 | 848 | |
| Louise Stanton | 423 | 132 | 177 | 35 | 823 | |
| Diamantis I. Tsilimigras | 301 | 160 | 137 | 55 | 886 | |
| Simone S.M. Ho | 233 | 167 | 145 | 25 | 772 | |
| Marianne Davies | 475 | 136 | 143 | 36 | 772 | |
| Ruey‐Kuen Hsieh | 305 | 96 | 100 | 48 | 708 | |
| Zhiming Wang | 276 | 170 | 122 | 60 | 894 | |
| Hollis W. Merrick | 254 | 153 | 92 | 47 | 745 | |
| L Giarelli | 164 | 380 | 146 | 59 | 841 | |
| Shiyou Wei | 146 | 230 | 117 | 49 | 844 |
All Works
Login with ORCID to disown or claim papers
Loading papers...